<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">The COVID-19 pandemic has put great pressure on healthcare workers and regulatory authorities to swiftly make treatment available [
 <xref rid="bb0035" ref-type="bibr">7</xref>]. Conducting clinical trials during this crisis is a heroic but difficult task, because clinicians have to provide patient care while they themselves are at risk of encountering infection. A substantial proportion of the registered COVID-19 interventional clinical trials are nonrandomized with small patient sizes, and many are observational studies [
 <xref rid="bb0005" ref-type="bibr">1</xref>]. Furthermore, the local epidemics associated with the pandemic are highly dynamic. Once the outbreak is under control locally, there might not be sufficient patients to be enrolled for ongoing studies in the region. For instance, two remdesivir trials in China (Clinical Trial Number
 <xref rid="p0050" ref-type="p">i</xref>: NCT04252664 and NCT04257656) were halted due to lack of patients with COVID-19
 <xref rid="p0055" ref-type="p">ii</xref>
 <sup>,</sup>
 <xref rid="p0060" ref-type="p">iii</xref>.
</p>
